Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 29, 2015 9:16 PM ET


Company Overview of Receptos, Inc.

Company Overview

Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product includes ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease. The company is also developing RPC4046, a monoclonal antibody, which is in phase II trials for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positive allosteric modulators that is in preclinical st...

3033 Science Park Road

Suite 300

San Diego, CA 92121

United States

Founded in 2008

68 Employees





Key Executives for Receptos, Inc.

Chief Executive Officer, President and Director
Age: 57
Total Annual Compensation: $534.4K
Co-Founder and Chief Technology Officer
Age: 55
Total Annual Compensation: $317.0K
Co-Founder and Chief Scientific Officer
Age: 59
Total Annual Compensation: $317.0K
Chief Financial Officer
Age: 45
Total Annual Compensation: $386.8K
Chief Medical officer
Age: 45
Total Annual Compensation: $437.8K
Compensation as of Fiscal Year 2014.

Receptos, Inc. Key Developments

Receptos, Inc. Announces Results of the Phase 2 Touchstone Trial - Report

Receptos, Inc. reported positive results for the maintenance period of TOUCHSTONE, the Phase 2 trial of ozanimod (formerly RPC1063) in ulcerative colitis (UC). The results showed that the study has met all efficacy endpoints with statistical significance in patients on the 1 mg dose of ozanimod after 32 weeks of treatment. Assessment Of Ozanimod Versus Placebo In Details- The aforesaid study evaluated the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1 mg) of ozanimod versus placebo. This randomized, double-blind, placebo-controlled trial was conducted in 199 patients with moderately-to-severely active UC across 57 sites in 13 countries. Receptos informed that the trial met its primary efficacy and all secondary endpoints for patients with 1 mg dose after 8 weeks of treatment in the induction period. The 103 patients, who achieved clinical response in the maintenance period at the eight week, continued with treatment for 24 more weeks. At week 32, all secondary end-points were positive and statistically significant for the 1 mg dose. The secondary endpoints at week 32 included clinical response, change in the industry standard Mayo score and mucosal improvement on endoscopy. Further, the proportion of patients in clinical remission at week 32 was statistically significant in favor of both the 1 mg group and the 0.5 mg group (p < 0.05) compared to placebo. Plans to start Phase 3Trial - In 2015, the Company plans to go ahead with a Phase 3 program to confirm the findings of Phase 2. The phase 3 trial would be conducted in patients with moderately-to-severely active UC. Furthermore, these results continue to suggest the potential for ozanimod to be used in the treatment of a related inflammatory bowel disease called Crohn's. The Company stated that it would be initiating a Phase 2 study of ozanimod for the treatment of Crohn's disease in 2015.

Celgene Corporation, Receptos, Inc. - M&A Call

To discuss the strategic acquisition of Receptos

Receptos, Inc.(NasdaqGS:RCPT) added to Russell 1000 Index

Receptos, Inc. has been added to Russell 1000 Index.

Similar Private Companies By Industry

Company Name Region
Royer Biomedical, Inc. United States
Sophion Bioscience Inc. United States
Prospex Medical, Inc. United States
Ambion, Inc. United States
CIMA LABS INC. United States

Recent Private Companies Transactions

July 14, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Receptos, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at